Does the media refer more to PRGO or ASMB?

In the previous week, Perrigo and Perrigo both had 1 articles in the media. Perrigo's average media sentiment score of 0.00 equaled Assembly Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ASMB or PCRX?

In the previous week, Pacira BioSciences had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 2 mentions for Pacira BioSciences and 1 mentions for Assembly Biosciences. Pacira BioSciences' average media sentiment score of 0.29 beat Assembly Biosciences' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OMER or ASMB?

In the previous week, Omeros had 6 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Omeros and 1 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.33 beat Assembly Biosciences' score of 0.00 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ASMB or CPIX?

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 53.14%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ASMB or CPIX?

In the previous week, Assembly Biosciences and Assembly Biosciences both had 1 articles in the media. Cumberland Pharmaceuticals' average media sentiment score of 0.51 beat Assembly Biosciences' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cumberland Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASMB or LLY?

In the previous week, Eli Lilly and Company had 131 more articles in the media than Assembly Biosciences. MarketBeat recorded 132 mentions for Eli Lilly and Company and 1 mentions for Assembly Biosciences. Eli Lilly and Company's average media sentiment score of 1.00 beat Assembly Biosciences' score of 0.00 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eli Lilly and Company 85 Very Positive mention(s) 13 Positive mention(s) 26 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

Assembly Biosciences (ASMB) Competitors

$28.73 +0.00 (+0.00%)

As of 09:41 AM Eastern

Compare

ASMB vs. PRGO, PCRX, OMER, CPIX, and LLY

Should you buy Assembly Biosciences stock or one of its competitors? MarketBeat compares Assembly Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assembly Biosciences include Perrigo (PRGO), Pacira BioSciences (PCRX), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Perrigo has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, Perrigo and Perrigo both had 1 articles in the media. Perrigo's average media sentiment score of 0.00 equaled Assembly Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Perrigo presently has a consensus price target of $19.33, suggesting a potential upside of 84.07%. Assembly Biosciences has a consensus price target of $44.00, suggesting a potential upside of 53.14%. Given Perrigo's higher probable upside, research analysts clearly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A
Assembly Biosciences	$72.30M	6.31	-$6.12M	-$0.11	N/A

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Summary

Assembly Biosciences beats Perrigo on 8 of the 14 factors compared between the two stocks.

How does Assembly Biosciences compare to Pacira BioSciences?

Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 53.14%. Pacira BioSciences has a consensus price target of $29.40, suggesting a potential upside of 14.82%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Pacira BioSciences	0.70%	10.24%	5.47%

Assembly Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Pacira BioSciences had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 2 mentions for Pacira BioSciences and 1 mentions for Assembly Biosciences. Pacira BioSciences' average media sentiment score of 0.29 beat Assembly Biosciences' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.31	-$6.12M	-$0.11	N/A
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.12	213.38

Summary

Pacira BioSciences beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Omeros?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Omeros had 6 more articles in the media than Assembly Biosciences. MarketBeat recorded 7 mentions for Omeros and 1 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.33 beat Assembly Biosciences' score of 0.00 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 267.33%. Assembly Biosciences has a consensus price target of $44.00, indicating a potential upside of 53.14%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts plainly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.78
Assembly Biosciences	$72.30M	6.31	-$6.12M	-$0.11	N/A

48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Omeros has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Summary

Omeros beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Assembly Biosciences and Assembly Biosciences both had 1 articles in the media. Cumberland Pharmaceuticals' average media sentiment score of 0.51 beat Assembly Biosciences' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cumberland Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.31	-$6.12M	-$0.11	N/A
Cumberland Pharmaceuticals	$44.52M	2.08	-$2.84M	-$0.49	N/A

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 53.14%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Assembly Biosciences has a net margin of -8.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Assembly Biosciences' return on equity of -4.21% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Assembly Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Summary

Assembly Biosciences beats Cumberland Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Assembly Biosciences compare to Eli Lilly and Company?

Assembly Biosciences (NASDAQ:ASMB) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Assembly Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eli Lilly and Company has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.31	-$6.12M	-$0.11	N/A
Eli Lilly and Company	$65.18B	17.67	$20.64B	$28.15	43.45

In the previous week, Eli Lilly and Company had 131 more articles in the media than Assembly Biosciences. MarketBeat recorded 132 mentions for Eli Lilly and Company and 1 mentions for Assembly Biosciences. Eli Lilly and Company's average media sentiment score of 1.00 beat Assembly Biosciences' score of 0.00 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eli Lilly and Company	85 Very Positive mention(s)	13 Positive mention(s)	26 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Eli Lilly and Company has a net margin of 34.98% compared to Assembly Biosciences' net margin of -8.98%. Eli Lilly and Company's return on equity of 105.77% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Eli Lilly and Company	34.98%	105.77%	23.76%

Assembly Biosciences presently has a consensus target price of $44.00, suggesting a potential upside of 53.14%. Eli Lilly and Company has a consensus target price of $1,255.89, suggesting a potential upside of 2.69%. Given Assembly Biosciences' higher probable upside, analysts plainly believe Assembly Biosciences is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

Eli Lilly and Company beats Assembly Biosciences on 14 of the 17 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$463.99M	$6.23B	$6.98B	$12.46B
Dividend Yield	N/A	0.64%	2.67%	7.39%
P/E Ratio	-265.43	8.68	27.13	24.24
Price / Sales	6.31	24.77	535.63	96.53
Price / Cash	N/A	8.93	49.24	56.96
Price / Book	2.20	4.41	10.96	6.38
Net Income	-$6.12M	$99.67M	$3.56B	$331.19M
7 Day Performance	3.57%	0.08%	-0.09%	-1.35%
1 Month Performance	26.46%	10.12%	5.22%	1.24%
1 Year Performance	53.48%	131.32%	30.29%	20.72%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	1.8967 of 5 stars	$28.73 +0.0%	$44.00 +53.1%	+58.8%	$463.99M	$72.30M	N/A	100	News Coverage
PRGO Perrigo	3.5149 of 5 stars	$11.01 +6.7%	$19.33 +75.7%	-61.1%	$1.52B	$4.18B	N/A	8,100
PCRX Pacira BioSciences	2.9424 of 5 stars	$25.39 +1.4%	$29.40 +15.8%	+10.1%	$999.05M	$734.86M	211.60	720
OMER Omeros	3.5333 of 5 stars	$9.28 -1.4%	$38.00 +309.5%	+227.2%	$671.69M	N/A	13.26	210
CPIX Cumberland Pharmaceuticals	0.4083 of 5 stars	$6.37 -10.7%	N/A	+103.6%	$95.42M	$44.52M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. PRGO, PCRX, OMER, CPIX, and LLY

How does Assembly Biosciences compare to Perrigo?

Summary

How does Assembly Biosciences compare to Pacira BioSciences?

Summary

How does Assembly Biosciences compare to Omeros?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. PRGO, PCRX, OMER, CPIX, and LLY

How does Assembly Biosciences compare to Perrigo?

Do institutionals and insiders have more ownership in PRGO or ASMB?

Which has more risk and volatility, PRGO or ASMB?

Does the media refer more to PRGO or ASMB?

Do analysts recommend PRGO or ASMB?

Which has stronger valuation and earnings, PRGO or ASMB?

Is PRGO or ASMB more profitable?

Summary

How does Assembly Biosciences compare to Pacira BioSciences?

Do insiders & institutionals hold more shares of ASMB or PCRX?

Do analysts rate ASMB or PCRX?

Is ASMB or PCRX more profitable?

Which has more risk and volatility, ASMB or PCRX?

Does the media prefer ASMB or PCRX?

Which has preferable earnings & valuation, ASMB or PCRX?

Summary

How does Assembly Biosciences compare to Omeros?

Does the media refer more to OMER or ASMB?

Do analysts rate OMER or ASMB?

Which has preferable valuation and earnings, OMER or ASMB?

Do institutionals & insiders believe in OMER or ASMB?

Which has more volatility & risk, OMER or ASMB?

Is OMER or ASMB more profitable?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Does the media favor ASMB or CPIX?

Which has stronger valuation and earnings, ASMB or CPIX?

Do analysts rate ASMB or CPIX?

Is ASMB or CPIX more profitable?

Do insiders & institutionals believe in ASMB or CPIX?

Which has more risk and volatility, ASMB or CPIX?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Which has more risk & volatility, ASMB or LLY?

Do institutionals and insiders believe in ASMB or LLY?

Which has better earnings & valuation, ASMB or LLY?

Does the media favor ASMB or LLY?

Is ASMB or LLY more profitable?

Do analysts rate ASMB or LLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools